Generate Biomedicines, Inc. Common Stock - Asset Resilience Ratio
Generate Biomedicines, Inc. Common Stock (GENB) has an Asset Resilience Ratio of 57.34% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see Generate Biomedicines, Inc. Common Stock (GENB) total assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Generate Biomedicines, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read GENB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Generate Biomedicines, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See Generate Biomedicines, Inc. Common Stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $322.06 Million | 57.34% |
| Total Liquid Assets | $322.06 Million | 57.34% |
Asset Resilience Insights
- Very High Liquidity: Generate Biomedicines, Inc. Common Stock maintains exceptional liquid asset reserves at 57.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Generate Biomedicines, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Generate Biomedicines, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.81% |
Annual Asset Resilience Ratio for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Generate Biomedicines, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.24% | $99.85 Million | $330.18 Million | -11.70pp |
| 2024-12-31 | 41.94% | $217.36 Million | $518.26 Million | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more